R01NIH · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESNIH

Molecular basis of antibiotic resilience in Mycobacterium tuberculosis

Fortune, Sarah (Contact)·HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH, MA·2024–2029·ACTIVE

Donate

INSTITUTION

HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH, MA

PRINCIPAL INVESTIGATOR

Fortune, Sarah (Contact)

FUNDING

$807K

YEAR

2024

MOONBASE SCORE

Still being scored

LOADING MOONBASE SCORE

Abstract

Summary We have identified a novel driver of treatment failure in Mycobacterium tuberculosis, termed antibiotic resilience, where the bacteria have improved recovery after antibiotic exposure. Population genomic and genetic studies implicate a novel transcriptional regulatory network in control of antibiotic resilience, which we will dissect through genomically informed structure-function studies and in treatment models.

R01NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESAnti-Infective Resistance and Targets Study Section [AIRT]throughmodelsresiliencepopulationgenomictranscriptionalgenomicallytuberculosisimplicateaftertermedgeneticbacterianoveltreatmentcontrol

Are you the primary organization running this research?

The two tools below are built for the principal investigator & host institution behind this project.